Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy.
- Author:
Le RONG
1
;
Zheng-rong LIU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Drug Resistance; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; drug therapy; Hormones; therapeutic use; Humans; Immunosuppressive Agents; therapeutic use; Isoxazoles; therapeutic use; Male; Middle Aged; Proteinuria; prevention & control; Time Factors; Treatment Outcome; Young Adult
- From: Journal of Southern Medical University 2007;27(6):893-894
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects and safety of leflunomide combined with hormone therapy for refractory IgA nephropathy.
METHODSThirteen patients with refractory IgA nephropathy were treated with leflunomide and hormone therapy, and the clinical data were collected and evaluated before and in weeks 2, 4, 8, 12, 16, 20 and 24 during the treatment.
RESULTSLeflunomide therapy significantly improved proteinuria (Plt;0.001) and increased serum albumin in these patients (Plt;0.001) but caused no significant changes in serum creatinine (Pgt;0.05). Only mild tolerable adverse effects were observed.
CONCLUSIONLeflunomide combined with hormone therapy can be one of the safety and effective choices for treatment of refractory IgA nephropathy.
